Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 12,313 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 12,313 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $28.82, for a total value of $354,860.66. Following the completion of the transaction, the chief financial officer directly owned 251,804 shares in the company, valued at $7,256,991.28. The trade was a 4.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.99, for a total value of $148,090.62.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The stock was sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $0.11 during midday trading on Friday, reaching $28.00. The company’s stock had a trading volume of 9,354,183 shares, compared to its average volume of 24,392,793. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30. The company has a market capitalization of $6.53 billion, a P/E ratio of -44.45 and a beta of 2.42. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The business’s fifty day simple moving average is $30.19 and its 200-day simple moving average is $27.60.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The company had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm’s quarterly revenue was up 38.2% on a year-over-year basis. During the same quarter last year, the company earned $0.17 EPS. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: COO Michael Chi sold 14,027 shares for approximately $398,000, and insider Soleil Boughton sold 6,236 shares for about $174,000. Both transactions were made under pre-arranged Rule 10b5-1 trading plans, limiting their value as direct signals of management’s current outlook, although the sales may still attract investor attention. SEC insider filing
• Negative Sentiment: Multiple investor-rights law firms publicized a securities class action against Hims & Hers and certain executives. The case covers investors who acquired HIMS securities from August 4, 2025, through July 29, 2026; the deadline to seek lead-plaintiff status is November 2, 2026. The repeated law-firm announcements appear to concern the same litigation rather than separate lawsuits. HIMS securities class action
• Negative Sentiment: The litigation alleges that Hims & Hers made materially misleading statements or omissions concerning privacy and data-sharing practices, billing, and other business conduct described in the FTC’s complaint. If the claims gain traction, potential consequences include legal costs, reputational damage, regulatory scrutiny, and pressure on future operating results. These allegations have not been proven in court. FTC-related lawsuit allegations

Analyst Ratings Changes

A number of research analysts have commented on HIMS shares. Needham & Company LLC increased their price objective on Hims & Hers Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. TD Cowen raised their price target on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Citigroup lowered their price objective on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Finally, Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $32.43.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Bienville Capital Management LLC bought a new stake in Hims & Hers Health in the second quarter valued at about $27,242,000. Engineers Gate Manager LP bought a new position in Hims & Hers Health during the second quarter worth about $232,000. Integrated Wealth Concepts LLC bought a new position in Hims & Hers Health during the second quarter worth about $147,000. Baird Financial Group Inc. grew its position in shares of Hims & Hers Health by 384.6% during the 2nd quarter. Baird Financial Group Inc. now owns 65,575 shares of the company’s stock worth $2,273,000 after buying an additional 52,043 shares during the period. Finally, Nykredit A S acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth about $222,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.